secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2026-01-06T23:59:59+00:00
Accession:  0001171843-26-000083
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics reports $209M cash, tovecimig PFS/OS data on track Q1 2026; appoints CCO and CMO
--------------------------------------------------------------------------------

- Cash and marketable securities estimated at $209M as of Dec 31, 2025; cash runway into 2028.
- Analyses of PFS and OS in tovecimig Phase 2/3 BTC trial expected late Q1 2026; BLA preparation underway.
- CTX-8371: third confirmed response in Hodgkin Lymphoma; expansions open in TNBC and NSCLC.
- Appointed Arjun Prasad as CCO and Cynthia Sirard as CMO effective January 2026.
- CTX-10726 Phase 1 initiation expected Q1 2026 with initial data in H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184326000083/0001171843-26-000083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184326000083/f8k_010626.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-000083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer